AbbVie Inc.

- AbbVie expects adjusted net interest expense of $2 billion in 2024 to finance the acquisitions of ImmunoGen and Cerevel. - The company anticipates dilution in earnings per share related to the recently closed ImmunoGen acquisition and the pending Cerevel acquisition. - No explicit mention of new fundraising through equity was made in the provided transcript. - The company is managing financing for acquisitions primarily through debt (implied by the net interest expense increase). - There is no direct indication of future equity offerings or other fundraising methods beyond the discussed acquisitions.

- AbbVie recently completed the acquisition of ImmunoGen, accelerating entry into the solid tumor market and strengthening their oncology pipeline. - The integration of ImmunoGen has been seamless, welcoming high-caliber talent into AbbVie. - The company remains on track for the pending acquisition of Cerevel, expected to close mid-year, which will further augment the neuroscience portfolio. - AbbVie continues to advance its long-term growth through R&D investments, including adding novel early-stage programs and partnerships in oncology and immunology. - Ongoing investments in consumer activation and new product launches, particularly highlighted for the aesthetics business in China, preparing for market recovery. - No specific dollar amounts or explicit capital expenditure figures were disclosed in the provided sections of the transcript.

- AbbVie expects strong revenue growth, specifically robust growth in 2025 and accelerating into 2026 and beyond, supported by expanding operating margins (Page 6). - The ex-Humira growth platform delivered over 15% revenue growth in Q1 2024, highlighting momentum in new products like Skyrizi and Rinvoq, with Skyrizi showing above 50% operational growth in its fifth year (Page 1, 4). - Continued double-digit revenue growth expected from other key products such as Venclexta, Vraylar, and Ubrelvy (Page 1). - The aesthetics business anticipates a recovery and positive growth in China starting in the second half of 2024 after near-term economic headwinds (Page 8). - Expect favorable contracting and stable volume for main products with multi-year contracts aiding steady access and pricing (Page 4). - The launch of new indications and products, including Skyrizi in ulcerative colitis and Elahere in oncology, will contribute to growth (Pages 1, 6).

- Robust revenue growth expected in 2025, accelerating further in 2026 and beyond due to Part D benefit redesign and margin expansion. - Typically, earnings are expected to grow faster than revenue on account of expanding operating margins. - Exception in 2025: net interest expense will dampen earnings growth somewhat, but solid earnings growth will still be delivered. - AbbVie raised adjusted EPS guidance for 2024 to a range of $11.13 to $11.33, up $0.16 from prior guidance, reflecting strong first-quarter results. - The diversified portfolio with multiple growth drivers supports a high-single-digit revenue CAGR through the end of the decade. - Consistent strong top and bottom-line performance driven by ex-Humira growth, with key products showing double-digit revenue growth.

The transcript provided from the PDF does not contain explicit information about the current or expected order book or pending orders for AbbVie. The discussion focuses mainly on price benefits related to formulary changes (e.g., CVS), various product performances (Humira, Skyrizi, aesthetics in China), contracting strategies, volume and price dynamics, market share, and some details about royalties and payments. Key relevant points about orders and sales context: - The one-time price benefit associated with CVS formulary changes affects volume declines and rebates. - Strong market share and stable fundamentals reported for Botox Cosmetic and Juvederm in aesthetics. - In China, aesthetics market expected to recover in the second half of 2024 after economic headwinds. - Skyrizi cash payment royalties in Q1 approximately $400 million. - Contracting activities underway for Skyrizi with expectations of favorable access in 2025. - Humira volume and pricing expected to track in line with earlier guidance; volume erosion mainly from CVS with some volume moving to other mechanisms like Skyrizi and Rinvoq. No specific numeric order book or pending orders details are provided.